Cardiovascular Systems Reports Fiscal 2016 Second-Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Leerink Partners Cut Price Target on Cardiovascular Systems (CSII) Following Disappointing 2Q and 3Q Guidance
January 22, 2016 9:22 AM ESTLeerink Partners maintained a Market Perform rating on Cardiovascular Systems (NASDAQ: CSII), and cut the price target to $13.00 (from $17.00), following the company's 2Q earnings report. For F2Q16, CSII reported sales of $41.4M, ~$2M below consensus. Also, management guided F3Q16 revenues well below consensus, yet again, at $40.5M-$42.0M vs. the Street at $46.1M. The guidance indicated what appears to be a more protracted impact than originally expected from the ongoing... More
Needham & Company Downgrades Cardiovascular Systems (CSII) to Underperform
January 22, 2016 7:34 AM ESTNeedham & Company downgraded Cardiovascular Systems (NASDAQ: CSII) from Buy to Underperform, saying positive revenue growth may be a year away.
Analyst Mike Matson commented, "CSII's F2Q16 revenue missed and EPS beat consensus and management guided below consensus for F2Q16. We are... More
Cardiovascular Systems (CSII) Tops Q2 EPS by 3c, Offers Q3 Guidance
January 21, 2016 4:15 PM ESTCardiovascular Systems (NASDAQ: CSII) reported Q2 EPS of ($0.47), $0.03 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $41.4 million versus the consensus estimate of $44.82 million.
GUIDANCE:
Cardiovascular Systems sees Q3 2016 EPS of ($0.42)-($0.45), versus the consensus of ($0.45).... More
